Literature DB >> 10506165

Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors.

B Z Paul1, J Jin, S P Kunapuli.   

Abstract

Thromboxane A(2) is a positive feedback lipid mediator produced following platelet activation. The G(q)-coupled thromboxane A(2) receptor subtype, TPalpha, and G(i)-coupled TPbeta subtype have been shown in human platelets. ADP-induced platelet aggregation requires concomitant signaling from two P2 receptor subtypes, P2Y1 and P2T(AC), coupled to G(q) and G(i), respectively. We investigated whether the stable thromboxane A(2) mimetic, (15S)-hydroxy-9, 11-epoxymethanoprosta-5Z,13E-dienoic acid (U46619), also causes platelet aggregation by concomitant signaling through G(q) and G(i), through co-activation of TPalpha and TPbeta receptor subtypes. Here we report that secretion blockade with Ro 31-8220, a protein kinase C inhibitor, completely inhibited U46619-induced, but not ADP- or thrombin-induced, platelet aggregation. Ro 31-8220 had no effect on U46619-induced intracellular calcium mobilization or platelet shape change. Furthermore, U46619-induced intracellular calcium mobilization and shape change were unaffected by A3P5P, a P2Y1 receptor-selective antagonist, and/or cyproheptadine, a 5-hydroxytryptamine subtype 2A receptor antagonist. Either Ro 31-8220 or AR-C66096, a P2T(AC) receptor selective antagonist, abolished U46619-induced inhibition of adenylyl cyclase. In addition, AR-C66096 drastically inhibited U46619-mediated platelet aggregation, which was further inhibited by yohimbine, an alpha(2A)-adrenergic receptor antagonist. Furthermore, inhibition of U46619-induced platelet aggregation by Ro 31-8220 was relieved by activation of the G(i) pathway by selective activation of either the P2T(AC) receptor or the alpha(2A)-adrenergic receptor. We conclude that whereas thromboxane A(2) causes intracellular calcium mobilization and shape change independently, thromboxane A(2)-induced inhibition of adenylyl cyclase and platelet aggregation depends exclusively upon secretion of other agonists that stimulate G(i)-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506165     DOI: 10.1074/jbc.274.41.29108

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  ADP and platelets: the end of the beginning.

Authors:  D Woulfe; J Yang; L Brass
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation.

Authors:  Todd M Quinton; Soochong Kim; Carol Dangelmaier; Robert T Dorsam; Jianguo Jin; James L Daniel; Satya P Kunapuli
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

Review 3.  Signaling during platelet adhesion and activation.

Authors:  Zhenyu Li; M Keegan Delaney; Kelly A O'Brien; Xiaoping Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

4.  Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI.

Authors:  Osamu Inoue; Katsue Suzuki-Inoue; Owen J T McCarty; Masaaki Moroi; Zaverio M Ruggeri; Thomas J Kunicki; Yukio Ozaki; Steve P Watson
Journal:  Blood       Date:  2005-10-11       Impact factor: 22.113

5.  Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets.

Authors:  Swaminathan Murugappan; Haripriya Shankar; Surya Bhamidipati; Robert T Dorsam; Jianguo Jin; Satya P Kunapuli
Journal:  Blood       Date:  2005-04-05       Impact factor: 22.113

6.  A membrane-based microfluidic device for controlling the flux of platelet agonists into flowing blood.

Authors:  Keith B Neeves; Scott L Diamond
Journal:  Lab Chip       Date:  2008-04-03       Impact factor: 6.799

Review 7.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

8.  P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.

Authors:  Anneke Bierend; Thomas Rau; Renke Maas; Edzard Schwedhelm; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

9.  RhoA downstream of G(q) and G(12/13) pathways regulates protease-activated receptor-mediated dense granule release in platelets.

Authors:  Jianguo Jin; Yingying Mao; Dafydd Thomas; Soochong Kim; James L Daniel; Satya P Kunapuli
Journal:  Biochem Pharmacol       Date:  2008-11-25       Impact factor: 5.858

Review 10.  Platelet thrombin receptor antagonism and atherothrombosis.

Authors:  Dominick J Angiolillo; Davide Capodanno; Shinya Goto
Journal:  Eur Heart J       Date:  2009-11-30       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.